Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain

• Autors principals: Yongsheng Liu (Autor), Anzhelika Vorobyeva (Autor), Tianqi Xu (Autor), Anna Orlova (Autor), Annika Loftenius (Autor), Theresa Bengtsson (Autor), Per Jonasson (Autor), Vladimir Tolmachev (Autor), Fredrik Y. Frejd (Autor)
• Format: Llibre
• Publicat: MDPI AG, 2021-06-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Radiolabeled Affibody-based targeting agent ¹⁷⁷Lu-ABY-027, a fusion of an anti-HER2 Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C-terminus, has demonstrated a promising biodistribution profile in mice; binding of the construct to albumi...